Navigation Links
Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study of HGS-ETR1 -

ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), have significant potential for use in the treatment of a broad range of cancers.

"We believe that HGS-ETR1 and HGS-ETR2 could offer novel, highly targeted therapeutic options that may prove useful in the treatment of a number of cancers," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "We note with pride that the Journal of Clinical Oncology, one of the field's most prestigious peer-reviewed publications, chose to publish the first human study of HGS-ETR1 earlier this month with an accompanying editorial - and, last week at AACR 2007, approximately 1500 cancer scientists and researchers attended our oral presentation of research results to date."

Results in the Journal of Clinical Oncology

The results of the first Phase 1 clinical trial of mapatumumab (HGS-ETR1) appeared in the April 10 issue of the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO). These results in 49 patients demonstrated that mapatumumab could be administered safely and repetitively to patients with advanced solid malignancies. The authors concluded that the absence of severe toxicities, and mapatumumab's ability to achieve blood levels consistent with antitumor activity in laboratory models, warrant further study of mapatumumab as a single agent and in combination with chemotherapy in a broad array of tumors.

Based on the initial Phase 1 results, along with extensive preclinical data, HGS initiated a broad clinical development program that included Phase 2 trials of HGS-ETR1 as a sin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:10/13/2008)... from Multiple Cancer Populations Facilitates ..., Mich., Oct. 13 /- Rubicon Genomics,...rick to amplify DNA samples for The,Cancer Atlas G...amplify and standardize total genomic,DNA from 3,0...The Rubicon,GenomePlex(TM) Whole Genome Amplificat...
(Date:10/12/2008)...lone and in Combination with Chemotherapy, FREMON...icals, Inc., a,development-stage pharmaceutical co...rence (RNAi)-based therapeutics, today announced t...on efficacy of siRNA targeting,its proprietary tar...) in,the edition dated October 1, 2008. The paper,...
(Date:10/12/2008)...NGTON, Oct. 12 /- Boston,Sc... results from an analysis,of nearly 7,500 patients...re designed to confirm the performance of the TAXU...t System in real-world practice. The,two-year pool... clinical,restenosis in patients with diabetes as ...
(Date:10/10/2008)...t. 10 /- Diplomat Specialty,Pharmacy ...d Diplomat,Specialty Pharmacy to be one of only th...l Therapy Optimization Study for Multiple Sclerosi...dy, is to examine the benefits of a,specialty phar...erence and,patient outcomes. Targeted patient outc...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 1Allscripts to Announce First Quarter 2008 Results on April 30 17431 2Allscripts to Announce First Quarter 2008 Results on April 30 17431 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 1Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 2Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 3Potential viral therapy weapon for difficult cancers is safe and effective in study 17428 4DURECT to Participate in Morgan Stanley Global Healthcare Conference 17424 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 1The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues 17419 2
... 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics...ase III multi- center clinical studies of ferumoxy... will be presented during,the National Kidney Foun...place April 10th through 14th in Orlando, Florida....be presented on,Wednesday, April 11, 2007 at appro...
...wed Complete Response or Reduction of,Lesion Size ... 05, 2007 /PRNewswire-FirstCall/ - Nventa,Biopharm...ation of,positive results from a clinical trial ex...spE7, an investigational therapeutic,vaccine for h...en,with the highest grade of cervical dysplasia (C...
Other Medicine Technology:Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6
(Date:10/10/2008)...gency of Record, CHICAGO, Oct. 10 /PRNewswire/ --...e launch of its "Delivering Small Miracles" campai...ng commitment to providing the highest,level of se...ecial Care,Nursery and Mother/Baby units., The ca...c relations and,advertising via billboards, geogra...
(Date:10/10/2008)...tCall/ -- Synvista,Therapeutics, Inc. (Amex: SYI ...ederici, 49, to its Board of Directors, expanding ...est Pharmaceutical Services as Vice President and,...is financial leadership,West Pharmaceutical,s rev...00 million. He has more than 20 years of public ac...
(Date:10/10/2008)...tCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a leadin...diagnostics, medical imaging systems and surgical ... of women, today announced plans to release its,fo...Tuesday, November 11,2008 after market close. In ... a conference call on Tuesday, November 11, 2008 a...
(Date:10/10/2008)... NuView Life Sciences Inc.,(NuView) has agreed to ...ce), including operations of the linear accelerato...exas. The Trace facility produces,Copper-64, Coppe...d in,molecular imaging and nuclear medicine. Paul ...e confident that by improving operational,efficien...
Breaking Medicine News(10 mins):Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 2Health News:Norwegian American Hospital Launches Awareness Campaign Targeting Hispanic, African-American and General-Market Moms 3Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2
...nity-built Riverina Cancer Care Centre is looking ... around reduction in prices, which will bring abou...ike. // This has happened following fears expresse...ople may avoid treatment owing to high costs. Kay ...
...hemselves on the plane to the gulf, not so much fo...s of people in the Gulf. // The demand for rabbit ...nd is much like the oasis in the desert, for what .... Gulf countries are exploring the options of imp...
... with birth defects is improved by incorporation o.... It has been known that folic acid supplementatio...rological birth defects such as spina bifida, anen... the effect of consumption of folic acid fortified...
...March issue of Paediatrics, Children's Hospital Bo...sumption of sugary drinks –home deliveries of nonc...ht loss. // Cara Ebbeling, PhD, and David Ludwig, ... Endocrinology, led the randomized, controlled tri...
Other Medicine News:Health News:A simple answer to teen weight loss: Reducing sugary drinks 2
Substrate Plasma for Factor XII Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XII.
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of Tissue Plasminogen Activator Antigen by ELISA Method, 96 tests.
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests.
Medicine Products: